Patient, specimen, and diagnosis characteristics in the Kamuzu Central Hospital pathology laboratory between July 1, 2011 and February 28, 2013.

<p>SD = standard deviation. *HIV status routinely collected beginning November 2012.</p

Timeline for development of pathology services at Kamuzu Central Hospital (KCH).

<p>Timeline for development of pathology services at Kamuzu Central Hospital (KCH).</p

Specimens received in the Kamuzu Central Hospital pathology laboratory between July 1, 2011 and February 28, 2013.

<p>Specimens received in the Kamuzu Central Hospital pathology laboratory between July 1, 2011 and February 28, 2013.</p

Immunohistochemistry stains being implemented in the Kamuzu Central Hospital pathology laboratory.

<p>HPV = human papillomavirus. LANA = latency-associated nuclear antigen. ER = estrogen receptor. PR = progesterone receptor.</p

Comparison of patient characteristics for premalignant/malignant diagnosis versus other diagnosis in the Kamuzu Central Hospital pathology laboratory between July 1, 2011 and February 28, 2013.

<p>SD = standard deviation. *Includes only specimens with known patient age, gender, or HIV status.</p

Associations of patient characteristics with premalignant/malignant and malignant diagnosis in the Kamuzu Central Hospital pathology database between July 1, 2011 and February 28, 2013.

<p>OR = odds ratio. CI = confidence interval. *Bivariable analyses include only specimens with known patient age (n = 2685), gender (n = 2748), or HIV status (n = 328). **Multivariable analyses include only 317 specimens with known patient age, gender, and HIV status.</p

Premalignant and malignant diagnoses in the Kamuzu Central Hospital pathology database between July 1, 2011 and February 28, 2013.

*<p>Includes only specimens with known HIV status and reported only when at least five specimens with known HIV status were available.</p

Risk factors for mortality among aggressive non-Hodgkin lymphoma patients in Lilongwe, Malawi.

<p>Risk factors for mortality among aggressive non-Hodgkin lymphoma patients in Lilongwe, Malawi.</p

Overall survival estimates for aggressive non-Hodgkin lymphoma in Lilongwe, Malawi.

<p>Overall survival estimates for aggressive non-Hodgkin lymphoma in Lilongwe, Malawi.</p

Overall survival for aggressive non-Hodgkin lymphoma in Lilongwe, Malawi.

<p>(A) Overall cohort with 95% confidence intervals. (B) Aggressive B-cell non-Hodgkin lymphoma (ABNHL) versus aggressive T-cell non-Hodgkin lymphoma (ATNHL). (C) Stratified by HIV status. (D) Stratified by international prognostic index (IPI). (E) Diffuse large B-cell lymphoma (DLBCL) stratified by HIV status. (F) DBLCL stratified by IPI.</p